Axsome Therapeutics Announces FDA Approval of AUVELITY® for the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
